Shahid I.
- Country
- Ireland
- Department
- Clinical Trials Research Unit
Research Overview
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
- Phase 3 Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 180 of 472 partner sites.
Specializations
Breast Cancer Specialization
This investigator specializes in advanced treatment approaches for hormone receptor-positive (HR+) breast cancer, with particular focus on HER2-negative metastatic breast cancer.
- Advanced/Metastatic Disease Management
- Hormone Receptor-Positive Cancer Treatment
- Systemic Therapy Innovation
The investigator explores innovative therapeutic combinations for patients with unresectable breast cancer conditions.
Treatment Approaches
The investigator focuses on developing combination therapy strategies involving novel therapeutic agents and established treatments like letrozole.
- First-line Treatment Development
- Therapeutic Combination Studies
- Targeted Treatment Approaches
Their work encompasses evaluation of treatment efficacy in previously untreated advanced breast cancer cases.
Clinical Assessment Focus
The investigator specializes in evaluating progression-free survival outcomes in breast cancer treatments through comparative analysis of therapeutic approaches.
- Treatment Response Assessment
- Clinical Efficacy Evaluation
- Therapeutic Outcome Analysis
Their research emphasizes objective measurement of treatment effectiveness in advanced breast cancer scenarios.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.